CA2405871A1 - 2-amino-3-hydroxy-4-tert-leucyl-amino-5-phenyl-pentanoic acid amide derivatives - Google Patents

2-amino-3-hydroxy-4-tert-leucyl-amino-5-phenyl-pentanoic acid amide derivatives Download PDF

Info

Publication number
CA2405871A1
CA2405871A1 CA002405871A CA2405871A CA2405871A1 CA 2405871 A1 CA2405871 A1 CA 2405871A1 CA 002405871 A CA002405871 A CA 002405871A CA 2405871 A CA2405871 A CA 2405871A CA 2405871 A1 CA2405871 A1 CA 2405871A1
Authority
CA
Canada
Prior art keywords
hydroxy
lower alkyl
methoxy
formula
benzyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002405871A
Other languages
English (en)
French (fr)
Inventor
Pascal Furet
Carlos Garcia-Echeverria
Patricia Imbach
Marc Lang
Johann Zimmermann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2405871A1 publication Critical patent/CA2405871A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0215—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing natural amino acids, forming a peptide bond via their side chain functional group, e.g. epsilon-Lys, gamma-Glu
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA002405871A 2000-05-25 2001-05-23 2-amino-3-hydroxy-4-tert-leucyl-amino-5-phenyl-pentanoic acid amide derivatives Abandoned CA2405871A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0012795.1 2000-05-25
GBGB0012795.1A GB0012795D0 (en) 2000-05-25 2000-05-25 Organic compounds
PCT/EP2001/005952 WO2001089282A2 (en) 2000-05-25 2001-05-23 2-amino-3-hydroxy-4-tert-leucyl-amino-5-phenyl-pentanoic acid amide derivatives

Publications (1)

Publication Number Publication Date
CA2405871A1 true CA2405871A1 (en) 2001-11-29

Family

ID=9892401

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002405871A Abandoned CA2405871A1 (en) 2000-05-25 2001-05-23 2-amino-3-hydroxy-4-tert-leucyl-amino-5-phenyl-pentanoic acid amide derivatives

Country Status (11)

Country Link
US (2) US20030166572A1 (cg-RX-API-DMAC10.html)
EP (1) EP1290012B1 (cg-RX-API-DMAC10.html)
JP (1) JP2003533541A (cg-RX-API-DMAC10.html)
AT (1) ATE325809T1 (cg-RX-API-DMAC10.html)
AU (1) AU2001266019A1 (cg-RX-API-DMAC10.html)
CA (1) CA2405871A1 (cg-RX-API-DMAC10.html)
DE (1) DE60119514T2 (cg-RX-API-DMAC10.html)
ES (1) ES2261422T3 (cg-RX-API-DMAC10.html)
GB (1) GB0012795D0 (cg-RX-API-DMAC10.html)
PT (1) PT1290012E (cg-RX-API-DMAC10.html)
WO (1) WO2001089282A2 (cg-RX-API-DMAC10.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20040762A1 (es) * 2002-11-27 2004-11-06 Elan Pharm Inc Ureas substituidas y carbamatos utiles para el tratamiento de la enfermedad de alzheimer
GB0504950D0 (en) * 2005-03-10 2005-04-20 Novartis Ag Organic compositions
US7919468B2 (en) 2005-04-07 2011-04-05 Centre National De La Recherche Scientifique (C.N.R.S.) Compounds useful as modulators of the proteasome activity
JP2011513278A (ja) * 2008-02-28 2011-04-28 ノバルティス アーゲー カンナビノイド受容体結合化合物およびオピオイドを含む組合せ
EP2399129B1 (en) 2009-02-20 2015-11-25 Michael P. Lisanti A method of diagnosis or prognosis of a neoplasm comprising determining the level of expression of a protein in stromal cells adjacent to the neoplasm
GB2523211B (en) 2012-01-27 2020-03-18 Univ Jefferson MCT protein inhibitor-related prognostic and therapeutic methods
EP2986290A4 (en) 2013-04-19 2017-01-04 Thomas Jefferson University Caveolin-1 related methods for treating glioblastoma with temozolomide
WO2019231935A1 (en) * 2018-05-29 2019-12-05 Omeros Corporation Masp-2 inhibitors and methods of use
AU2020395306B2 (en) 2019-12-04 2025-04-24 Omeros Corporation MASP-2 inhibitors and methods of use

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5538997A (en) * 1993-03-12 1996-07-23 Sandoz Ltd. 2,4-diamino-3-hydroxycarboxylic acid derivatives
EP0982317A1 (en) * 1998-08-26 2000-03-01 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Bivalent inhibitors of the proteasome
ATE270268T1 (de) * 1999-04-27 2004-07-15 Novartis Pharma Gmbh 2,4-diamino-3-hydroxycarboxylsäurederivate als proteasome inhibitoren

Also Published As

Publication number Publication date
AU2001266019A1 (en) 2001-12-03
US20030166572A1 (en) 2003-09-04
PT1290012E (pt) 2006-09-29
EP1290012A2 (en) 2003-03-12
JP2003533541A (ja) 2003-11-11
WO2001089282A3 (en) 2002-05-10
US20060205673A1 (en) 2006-09-14
GB0012795D0 (en) 2000-07-19
EP1290012B1 (en) 2006-05-10
WO2001089282A2 (en) 2001-11-29
DE60119514D1 (de) 2006-06-14
DE60119514T2 (de) 2006-10-05
ATE325809T1 (de) 2006-06-15
ES2261422T3 (es) 2006-11-16

Similar Documents

Publication Publication Date Title
US6933290B2 (en) 2-{N-(2-amino-3-(heteroaryl or aryl)propionyl)-aminoacyl}-amino}-alkylboronic acid derivatives
CA2761489C (en) High penetration prodrug compositions of peptides and peptide-related compounds
US10800752B2 (en) Substituted naphtho[2,3-b]furans as water-soluble prodrugs for preventing and/or treating cancer
SK63498A3 (en) Novel macrocyclic compounds as metalloprotease inhibitors
CN100357267C (zh) 2,4-二氨基-3-羟基羧酸衍生物在制备作为蛋白酶体抑制剂的药物中的用途
EP0374097A2 (de) Verwendung von Peptidisosteren als retrovirale Proteasehemmer
EP1290012B1 (en) 2-amino-3-hydroxy-4-tert-leucyl-amino-5-phenyl-pentanoic acid amide derivatives
CA2005340A1 (en) Retroviral protease inhibitors
CN111187202B (zh) Nmda拮抗剂前药
WO2011106721A1 (en) Flurbiprofen analogs and methods of use in treating cancer
JPH10504040A (ja) Ge2270及びge2270−様抗生物質の塩基性プロリン−アミド誘導体
JP3987586B2 (ja) 2,4−ジアミノ−3−ヒドロキシカルボン酸誘導体
JP4604161B2 (ja) フェニルアラニン誘導体
JP2003533541A5 (cg-RX-API-DMAC10.html)
CN101395143A (zh) 用于治疗疟疾或aids的氮杂杂环化合物
KR100437670B1 (ko) (s)-이성체형태의인돌린설포닐우레아유도체
HK1044931B (en) Use of 2,4-diamino-3-hydroxycarboxylic acid derivatives as proteasome inhibitors
JPH08165274A (ja) Hivプロテアーゼ阻害剤
KR20110115048A (ko) 신규한 아릴설포닐이미다졸론 유도체 및 이를 함유하는 항암제 조성물
JPH0840886A (ja) 長鎖の非分枝鎖状アルキルアミドおよびそれを含有する抗増殖および炎症抑制医薬品
MXPA01006719A (en) Selective inhibitors of mmp-12

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued